Form 4: Bristol-Myers Squibb Executive Adam Lenkowsky Reports Changes in Beneficial Ownership

EVP, Chief Commercial Officer of Bristol-Myers Squibb, Adam Lenkowsky, reports transactions involving common stock and derivative securities, including acquisitions, disposals, and vesting of market share units and performance shares.

Summary

• Adam Lenkowsky, EVP, Chief Commercial Officer of Bristol-Myers Squibb, filed a Form 4 detailing changes in his beneficial ownership of the company's securities on March 12, 2025.
• The reported transactions occurred on March 10, 2025, and include the acquisition and disposal of common stock, as well as the vesting of market share units and performance shares.
• Lenkowsky acquired shares through the vesting of market share units and performance shares, and disposed of shares to cover tax obligations.
• The transactions resulted in an increase in Lenkowsky's directly held common stock to 12,439 shares and indirectly held shares through the BMS Savings and Investment Program to 4,525.619 shares.
• He also holds derivative securities, including market share units and performance shares, which will convert into common stock in the future.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions. The vesting of shares is a positive sign, but the disposal for tax obligations is a neutral event.

Positives

• The vesting of market share units and performance shares indicates that the company is meeting certain performance targets.
• The executive's increased holdings of company stock could be seen as a positive sign of confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while a normal occurrence, does reduce the executive's overall holdings.

Risks

• The value of market share units and performance shares is dependent on the company's future stock price and performance, which are subject to market risks.
• Changes in the company's performance or market conditions could impact the value of these derivative securities.

Future Outlook

The document details future vesting dates for market share units and performance shares, indicating continued equity-based compensation for the executive.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are closely monitored by investors for insights into management's confidence in the company's prospects. This filing is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Executive compensation packages at large pharmaceutical companies like Bristol-Myers Squibb typically include a mix of salary, bonus, stock options, and restricted stock units.
• The vesting schedules and performance-based criteria for market share units and performance shares are generally aligned with industry best practices to incentivize long-term value creation.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• However, executive stock ownership is often viewed as a signal of alignment with shareholder interests.

Next Steps

• The executive will continue to hold and potentially vest in additional market share units and performance shares in the future.
• Future Form 4 filings will be required to report any further changes in beneficial ownership.

Key Dates